NKT Therapeutics accesses BioWa's antibody technology
This article was originally published in Scrip
Executive Summary
NKT Therapeutics, a private US firm developing killer T-cell-based therapeutics, has acquired rights to use BioWa's antibody efficacy and potency-enhancing technology for undisclosed terms.